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OBJECTIVES: 1) To identify antidiabetic products approved with a Patient-
Reported Outcome (PRO) labeling claim in Europe and the USA, and 2) to list the 
differences found in Europe versus the USA in terms of products and labeling. 
METHODS: The search was performed on the FDA- and EMA-approved medicinal 
product labels (from 1995 to August 2012 inclusive). The review was conducted 
through a systematic manual review of antidiabetic product labelings. RESULTS: 
A total of 96 antidiabetic products were retrieved: 53 approved by the EMA, 43 by 
the FDA (generics excluded). Only two products with a PRO labeling claim were 
found in Europe (i.e., Insulin Glulisin and Exenatid), and none in the USA. PROs 
identified in both claims were self-monitored blood glucose (SMBG) profiles and 
were used as secondary endpoints. Although Insulin Glulisin and Exenatid were 
also approved by the FDA (on the same studies used in Europe) their US label did 
not mention any results based on SMBG profiles. Reasons for not including them 
in the label were not given in the corresponding medical reviews. However, the 
analysis of other products’ reviews, such as Insulin Aspart or Liraglutide, showed 
a reluctance from reviewers to include results based on SMBG profiles in the 
labels. Reviewers questioned the validity of the glucose profiles based on self-
collected readings because of compliance issues and of a lower degree of 
accuracy of values obtained from glucometers versus lab measures in a clinic. 
Although measured in some cases, other PROs, such as quality of life or 
treatment satisfaction, were never considered for inclusion in labeling with any 
reasons given. CONCLUSIONS: Our review showed that Patient-Reported 
Outcomes are rarely included in antidiabetic product labels in Europe and in the 
US. Other than discussions on the validity of self-monitored blood glucose 
profiles, reasons for such non-inclusion were not provided.  
 
PDB77  
A CROSS SECTIONAL ASSESSMENT OF KNOWLEDGE TOWARDS DIABETES 
MELLITUS AMONG URBAN POOR POPULATION OF PENANG, MALAYSIA  
Hassali MA1, Saleem F1, Chua GN2, Haq N1, Aljadhey H3 
1Universiti Sains Malaysia, Penang, Malaysia, 2Universiti Sains Malaysia, Penang, P. Penang, 
Malaysia, 3King Saud University, Riyadh, Riyadh, Saudi Arabia  
OBJECTIVES: To assess diabetes related knowledge among urban poor 
population of Tunku village, Jelutong, Penang, Malaysia. METHODS: A 
questionnaire based, cross-sectional observational study was carried out. All 
residence of the area (age 18 and above) were targeted. The study was conducted 
from September to November 2012. Descriptive statistics were applied to 
summarize the data. All analyses were performed by using Statistical Package for 
Social Sciences (SPSS) software version 17. RESULTS: A total of 104 residents 
agreed to participate in the study. The cohort was dominated by females (n=70, 
67.3%) and ethnic group of Malay (n=71, 68.3%) with mean age of 56.9±13.4 years. 
More than half (n=61, 58.7%) of the respondents were considered as low income 
earners as the monthly household income was less than Ringgit Malaysia 1000. 
Ninety one (87.5%) knew the definition of diabetes whereas (n=77, 74%) had 
knowledge about the normal glucose level in the body). Eight six (82.7%) had the 
knowledge about the complications associated with diabetes. Majority of them 
believed that regular exercise can control diabetes, whereas only 25 (24%) 
believed that diet modification can help in managing the diabetes. Twenty one 
(20.2%) stated that diabetes is a disease of old age. The mean diabetes knowledge 
score was 6.92±2.027 out of 10. CONCLUSIONS: The study revealed that the 
respondent had adequate diabetes related knowledge. However, certain diabetes 
related attributes were lacking in the population. It is advisable that efforts 
should be made to educate the residents of the urban poor areas for adequate 
management of diabetes.  
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OBJECTIVES: The impact of memory problems (MPs) on patient insulin taking 
behavior, functioning, well-being and diabetes management is not well 
understood. The purpose of this study was to examine these impacts in China, 
the country with the largest diabetes population in the world. METHODS: MPs 
were defined as: unintentionally forgetting (UF) to take insulin, questioning 
whether or not insulin had been taken (QT), or questioning how much insulin 
was taken (QD). A web-based survey examining circumstances leading to the MP, 
corrective actions taken, impact on health well-being and diabetes management 
was conducted. RESULTS: A total of 354 respondents (217 or 61.3% Type 1, 137 or 
38.7% Type 2) completed the survey, 59% male, mean age of 43.2 (±13.4, 25-70) 
and mean age of diabetes onset of 36.9 (±12.0, 2-65). The prevalence of MPs was 
high, with 74.6% forgetting, 83.1% questioning whether taken and 65.8% 
questioning how much insulin taken in the past month. MPs occurred most 
frequently at work and the major reasons for the MP were being tired or busy. 
Depending upon MP type, between 16.2% (QD) – 20.5% (UF) of respondents 
skipped their insulin dose and waited for next scheduled dose when 
experiencing a MP and then required between 4.9 (QD)–10.1 (UF) hours to return 
to a normal blood glucose range. Patients conducted between 1.6 (QT/QD) –4.6 
(UF) extra BG monitoring tests and reported a moderate negative impact on their 
physical, emotional and functioning as well as their ability to function at work. 
Further, between 16.2% (QT) and 40.9% (UF) visited their health care provider as a 
result of a MP. Economic implications include cost of additional BG monitoring 
strips, lost work productivity and health care resource utilization. 
CONCLUSIONS: These findings suggest that MPs in China carry financial burden, 
impact patients functioning and well-being and may be serious obstacles to 
optimal diabetes control.  
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OBJECTIVES: To qualitatively examine issues regarding unintentional dosing 
irregularities due to memory issues which may impact insulin taking behavior in 
people with diabetes. METHODS: Seven focus groups and eight individual 
interviews were held (Canada, Germany, China). Respondents were recruited 
who had experienced at least two instances in the previous three months of 
forgetting the insulin dose, time/amount taken, or being unsure if they took their 
insulin. Transcripts were coded thematically, based on grounded theoretical 
approach. RESULTS: Sixty-four people participated: mean age 50.1 (range 18 to 
72), (34% type 1, 66% type 2). Analysis generated 6 domains: behaviors forgotten, 
reasons for forgetting, how they became aware that they had forgotten their 
insulin, consequences of forgetting, corrective actions, and the emotional impact 
of forgetting insulin. Respondents reported forgetting both bolus and basal 
insulin doses and often felt uncertain about if they administered their insulin 
dose, the dose amount or time taken. Major reasons for these memory issues 
were: forgetting due to disruptions in their daily routine, distraction by social 
events, minor interruptions, and being generally busy. They became aware they 
forgot due to their own reminder systems as well as symptoms of hyperglycemia 
and blood glucose testing. People employ a wide variety of strategies and 
corrective actions when they think they have forgotten and often monitor their 
blood glucose more frequently following dosing irregularities. Further, patients 
often question as to whether or not they took their insulin with greater 
frequency than times when they actually forgot and worry about the impact of 
these behaviors on maintaining stable blood glucose control. CONCLUSIONS: 
Unintentional memory issues does impact insulin taking behavior , leads to 
dosing irregularities and contributes to patient uncertainty and worry about their 
diabetes management. Insulin strategies that assist patients in managing 
memory related dosing issues may reduce treatment costs, improve adherence 
and treatment outcomes.  
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OBJECTIVES: Hypoglycemia symptoms are associated with a high level of fear. 
This study examined the relationships among symptomatic hypoglycemia, fear 
of hypoglycemia, and HRQOL, and focused on whether fear of hypoglycemia is 
independently associated with lower HRQOL. METHODS: Data were collected 
from mail surveys and enrollment information from a sample of adult 
commercial health plan enrollees (n=813) with indentified type-2 diabetes during 
a 12-month period. Patient’s HRQOL was evaluated by the EuroQol (EQ)-5D scale 
and SF-12 scale, and the hypoglycemia fear scale (HFS) was used to assess fear of 
hypoglycemia. We specified two ordinary least square (OLS) models of HRQOL, 
controlling for demographics and illness characteristics. We compared the 
regression coefficients and statistical inferences from two OLS models: Model 1 
included only one variable of hypoglycemia symptoms; Model 2 included both 
hypoglycemia symptoms and HFS score. RESULTS: Model 1: The hypoglycemia 
symptoms alone were associated with worse HRQOL as measured by SF-12 
mental component summary (MCS) and physical component summary (PCS) 
scores and EQ-5D utility score (all p-values <0.05). Model 2: The variable of 
hypoglycemia symptoms was significantly associated only with SF-12 MCS score. 
In contrast, the HFS total score was significantly associated with all three scores 
of HRQOL. The survey analysis also found that the symptoms of hypoglycemia, 
socioeconomic factors (e.g., Hispanic ethnicity), and longer diabetes duration 
were associated with higher level of hypoglycemia fear, whereas higher income 
level, white race, and treatment without either sulfonylurea or insulin were 
associated with lower hypoglycemia fear (all p-values <0.05). CONCLUSIONS: The 
fear and the experience of symptomatic hypoglycemia were both independently 
associated with lower HRQOL (overall health status, mental and physical health). 
Interventions (e.g., patient education programs) can be designed to address the 
fear of hypoglycemia. Choosing a therapy with a lower propensity for 
hypoglycemia may also positively impact QOL.  
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OBJECTIVES: Patients’ with diabetic neuropathy may or may not show 
symptoms. If its progression is not stopped at the earliest, it may lead to foot 
ulceration and amputation. This study was conducted to assess the role of 
Quantitative Sensory Testing (QST) in detection of diabetic neuropathy. Glycated 
hemoglobin (HbA1c) and age are two of the major risk factors for diabetic 
neuropathy. So, relationship of thermal thresholds was seen with HbA1c as well 
as age. METHODS: This was a retrospective observational study conducted on 
